Milrinone Therapy in Severe Heart Failure

Introduction to Milrinone Therapy

The American College of Cardiology recommends milrinone for patients with documented severe systolic dysfunction, low blood pressure, and low cardiac index to maintain systemic perfusion 1
Milrinone is reasonable for bridge therapy in stage D heart failure patients awaiting mechanical circulatory support or cardiac transplantation (Class IIa recommendation) 1

If blood pressure stability is a concern, consider dividing the bolus into five equal aliquots administered over 10 minutes each 2
Adjust infusion rates based on creatinine clearance, with a maximum total daily dose not exceeding 1.13 mg/kg/day 2

Milrinone produces both inotropic and vasodilatory effects through phosphodiesterase-3 inhibition, resulting in decreased pulmonary vascular resistance 3, 4
The European Heart Journal notes that milrinone's mechanism of action is distal to beta-adrenergic receptors, maintaining effectiveness despite receptor downregulation 3

The American College of Cardiology states that milrinone is not recommended for normotensive patients with acute decompensated heart failure without evidence of decreased organ perfusion (Class III recommendation) 1
Long-term continuous or intermittent therapy outside of palliative care or bridge to advanced therapies is harmful (Class III: Harm) 1

The American College of Cardiology recommends monitoring renal function closely as milrinone accumulates in renal impairment 1
Target mean arterial pressure should be ≥65 mmHg 2
Discontinue milrinone immediately if hypotension or arrhythmias develop 2

Milrinone is preferred over dobutamine in patients on beta-blocker therapy because its mechanism of action is distal to beta-adrenergic receptors, maintaining effectiveness despite receptor downregulation 3, 2
The European Heart Journal suggests tapering milrinone very gradually (decrease by 2 mcg/kg/min every other day) 3

Milrinone's hemodynamic profile is intermediate between pure vasodilators (nitroprusside) and predominant inotropes (dobutamine) 3
Unlike dobutamine, milrinone does not depend on beta-adrenergic receptors and maintains action when receptors are downregulated 2, 4

The American College of Cardiology/American Heart Association (ACC/AHA) guidelines state that continuous intravenous milrinone may be used in patients who cannot be weaned from intravenous to oral therapy despite repeated attempts, particularly as bridge to transplantation or as palliative therapy in end-stage disease 5, 6, 7
The American College of Cardiology recommends that intermittent infusions of milrinone should not be used and lack evidence of efficacy 8, 9, 10
Continuous infusions are acceptable only in specific circumstances: as bridge to transplantation or as palliative therapy in Stage D heart failure 5, 6, 7

The American College of Cardiology guidelines require documented severe systolic dysfunction, refractory symptoms despite optimal medical therapy, failed weaning attempts, and symptomatic improvement on therapy for continuous milrinone infusion to be medically indicated 5, 6, 7
Refractory symptoms despite optimal medical therapy, including multiple hospitalizations for cardiogenic shock and decompensated heart failure, are required for medical necessity 6, 7
Failed weaning attempts from intravenous inotropic support despite repeated attempts are necessary for medical necessity 5, 6

The American College of Cardiology recommends milrinone as bridge therapy in Stage D heart failure patients awaiting mechanical circulatory support or cardiac transplantation 5, 6
Continuous milrinone may provide palliation of symptoms as part of an overall plan to allow the patient to die with comfort at home if the patient is not a transplant or mechanical circulatory support candidate 5, 6, 7

The American College of Cardiology warns that indefinite continuation of home milrinone without a clear goal presents a major burden to family and health services and may ultimately increase the risk of death 5, 6
Clear documentation of failed weaning attempts, explicit designation as bridge therapy or palliative care, regular reassessment of transplant/LVAD candidacy, and family understanding of risks and goals of care are required for continuation of milrinone infusion 5, 6, 9